The correlation of anti-β2-glycoprotein I antibody with complement activation in patients with idiopathic membranous nephropathy.
Anti-PLA2R
Anti-β2GPI
C4d
Complement activation
Idiopathic membranous nephropathy
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
18
07
2020
accepted:
27
10
2020
pubmed:
5
1
2021
medline:
1
10
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
This study evaluated the correlation of anti-β2-glycoprotein I (anti-β2-GPI) antibodies with complement activation in patients with idiopathic membranous nephropathy (IMN). Thirty-two IMN patients with positive anti-β2-GPI antibody were enrolled, and 32 age- and sex-matched IMN patients with negative anti-β2-GPI antibody were randomly enrolled as controls. The frozen serum samples of these 64 patients were collected for detection of anti-phospholipase A2 receptor (PLA2R) antibody and the activity of three complement pathways. Paraffin specimens of the kidney tissues of these 64 patients were collected for immunohistochemical staining of C4d. IMN patients with positive anti-β2-GPI antibody had a significant decline of the residual complement activity of alternative pathway than those with negative anti-β2-GPI antibody (37.4 ± 21.2% vs 65.7 ± 50.5%, P = 0.021). The positive rate of kidney C4d staining in IMN patients with and without anti-β2-GPI was 65.6 and 81.2%, with no significant difference (P = 0.257). Patients with and without anti-β2-GPI had the same positive rate of anti-PLA2R antibody. Anti-β2-GPI antibody was associated with alternative complement activation in patients with IMN.
Identifiants
pubmed: 33392885
doi: 10.1007/s11255-020-02698-2
pii: 10.1007/s11255-020-02698-2
doi:
Substances chimiques
Autoantibodies
0
beta 2-Glycoprotein I
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
955-959Références
Couser WG (2017) Primary membranous nephropathy. Clin J Am Soc Nephrol 12:983–997
doi: 10.2215/CJN.11761116
Cattran DC, Brenchley PE (2017) Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int 91:566–574
doi: 10.1016/j.kint.2016.09.048
Beck LH, Bonegio RG, Lambeau G et al (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21
doi: 10.1056/NEJMoa0810457
Tomas NM, Beck LH, Meyer-Schwesinger C et al (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371:2277–2287
doi: 10.1056/NEJMoa1409354
Sethi S, Debiec H, Madden B et al (2020) Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 97:163–174
doi: 10.1016/j.kint.2019.09.014
Pozdzik A, Brochériou I, David C et al (2018) Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management. Biomed Res Int 2018:6281054
doi: 10.1155/2018/6281054
Ma H, Sandor DG, Beck LH Jr (2013) The role of complement in membranous nephropathy. Semin Nephrol 33:531–542
doi: 10.1016/j.semnephrol.2013.08.004
Francis JM, Beck LH Jr, Salant DJ (2016) Membranous nephropathy: a journey from bench to bedside. Am J Kidney Dis 68:138–147
doi: 10.1053/j.ajkd.2016.01.030
Salant DJ (2019) Unmet challenges in membranous nephropathy. Curr Opin Nephrol Hypertens 28:70–76
doi: 10.1097/MNH.0000000000000459
Sciascia S, Radin M (2018) Thrombotic antiphospholipid syndrome. Lupus 27:21–27
doi: 10.1177/0961203318801686
Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346:752–763
doi: 10.1056/NEJMra002974
Levy Y, Ziporen L, Gilburd B et al (1996) Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice. Hum Antibodies Hybridomas 7:91–96
doi: 10.3233/HAB-1996-7301
Sinico RA, Cavazzana I, Nuzzo M et al (2010) Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol 5:1211–1217
doi: 10.2215/CJN.00460110
Zhang Q, Wang Y, Xu Y et al (2019) Antiphospholipid antibodies in patients with membranous nephropathy. Nephron 143:228–233
doi: 10.1159/000501857
Val-Bernal JF, Garijo MF, Val D et al (2011) C4d immunohistochemical staining is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis. Histol Histopathol 26:1391–1397
pubmed: 21938676
Borza DB, Zhang JJ, Beck LH Jr et al (2013) Mouse models of membranous nephropathy: the road less travelled by. Am J Clin Exp Immunol 2:135–145
pubmed: 23885331
pmcid: 3714174
Jelezarova E, Lutz HU (2005) IgG naturally occurring antibodies stabilize and promote the generation of the alternative complement pathway C3 convertase. Mol Immunol 42:1393–1403
doi: 10.1016/j.molimm.2004.12.014
Luo W, Olaru F, Miner JH et al (2018) Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy. Front Immunol 9:1433
doi: 10.3389/fimmu.2018.01433
Pierangeli SS, Vega-Ostertag M, Liu X et al (2005) Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci 1051:413–420
doi: 10.1196/annals.1361.083
Ruiz-Irastorza G, Crowther M, Branch W et al (2010) Antiphospholipid syndrome. Lancet 376:1498–1509
doi: 10.1016/S0140-6736(10)60709-X
Oku K, Atsumi T, Bohgaki M et al (2009) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68:1030–1035
doi: 10.1136/ard.2008.090670
Zhou Y, Chen P, Li Y (2019) Association between antiphospholipid antibodies and factor Bb in lupus nephritis patients with glomerular microthrombosis. Int J Rheum Dis 22:2185–2190
doi: 10.1111/1756-185X.13733
Lionaki S, Derebail VK, Hogan SL et al (2012) Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7:43–51
doi: 10.2215/CJN.04250511
Barbour SJ, Greenwald A, Djurdjev O et al (2012) Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 81:190–195
doi: 10.1038/ki.2011.312